

ADVANCED MEDICAL SOLUTIONS GROUP PLC

Annual General Meeting

12th June 2012



A year of progress
and delivery

2011 Financial highlights



- Revenue up 8% to £34.4 million (2010: £31.9 million) at actual and 9% at constant currency¹
- Operating profit (pre-exceptional items²) up 20% to £6.4 million (2010: £5.3 million)
- Basic earnings per share (pre-exceptional items²) up 11% to 4.26p (2010: 3.83p)
- Cash inflow from operating activities (pre-exceptional items²) of £5.5 million (2010: £8.1 million)
- After RESORBA acquisition, net debt³ was £13.4 million at 31 Dec 2011 (2010: net funds £3.9 million)
- Proposed final DPS of 0.305p making a full year dividend of 0.45p per share (2010: 0.38p)

¹ Constant currency removes the effect of currency movements by re-translating the current year's performance at the previous year's exchange rates

² Exceptional costs of £1.8 million were incurred in relation to the RESORBA acquisition (2010: exceptional costs of £1.0 million were incurred on the Winsford facility)

³ Net debt is defined as financial liabilities less cash, cash equivalents and short term investments

Advanced woundcare 2011 progress & future focus



➤ NHS - ActivHeal® (revenue up 73%)

- rebrand continues to improve compliance
- delivering on promise of cost savings without compromise on clinical effectiveness is resonating very strongly
- continue to strengthen brand awareness - case studies, clinical papers, training literature
- expand and upgrade foam range - tri-laminate dressings



➤ Foam (revenue up 49%)

- new size and shape designs launched
- plant investment producing clear benefits and increased capacity
- significant European customer launches in 2011
- Tri-laminate capability from H2 2012



Advanced woundcare 2011 progress & future focus



- Silver alginate (revenue down 2%)
 - gains in the US (+7%), offset by a major partner de-stocking in UK/Europe - now ended
 - AMS technical and clinical support continuing to drive partner ability to gain market share

- Winsford facility delivering further efficiencies and margin improvements
 - 180 basis points in woundcare business in 2011
 - target 300 basis points improvement over 3 years.

- Increased focus on higher margin products and erosion of low margin product tail



Wound closure & sealants 2011 progress & future focus

➤ LiquiBand® - USA

- end market sales increased more than threefold in 2011 compared with 2010
- LiquiBand® achieved a full year market volume share of
 - 5% in the hospital market
 - 8% in the alternative site market
- ex-factory revenues at similar level to 2010



➤ Increasingly competitive US market

- launch of new product LiquiBand® Flex
- expanded routes to market - network of specialist OR focused regional distributors
- significant opportunities to drive further growth

Wound closure & sealants

2011 progress & future focus



➤ LiquiBand® - other markets

- non US markets up 13% year-on-year
- small but encouraging sales in both Japan and Canada
- regulatory approval process underway in China & Russia



➤ LiquiBand® - next generation products

- focus on obtaining LiquiBand® approval for internal fixation e.g. placement of hernia meshes
- good progress on laparoscopic delivery system - now passed concept feasibility
- launch anticipated in 2013, subject to successful development and validation



➤ InteguSeal®

- revenues continue at low level
- alternative route-to-market options being progressed for 2012 including direct surgical sales in Germany



Acquisition strategy

Resorba transaction rationale



Aquisition Strategy - integration planning



Phase 1 activity	Q1	Q2	Q3	Q4
LiquiBand® Flex launch in Germany	Rep Training	Launch		
LiquiBand® launch in Czech Republic		Rep training	Launch	
LiquiBand® regulatory approval Russia	Regulatory preparation	Russian clinical study and product filing	Market approval	Launch
LiquiBand® approval for use in oral surgery	Regulatory preparation	Clinical & technical data gathering	Product regulatory filing	Market approval end Q4
InteguSeal® launch in Germany	Market research & KOL activity	Agreement with Kimberley-Clark	Rep training and market re-launch	
Suture sales UK	Market research & strategy development	Key purchasing meetings		Contract awards
Collagen sales UK		Rep training	Product promotion	Launch

Outlook



- 2012 has started well and promises to be an exciting year for AMS Group
- AMS Group brands expected to be over 50% of revenue in 2012
- LiquiBand® expected to gain further market share in the US
- RESORBA commercial synergies on track to be earnings enhancing in first year
- Exciting Group R&D pipeline
- We remain positive about the future prospects of the Group